Recent share performance and business scale

With no single headline event driving market attention, Elevance Health (ELV) has drawn interest through its recent share performance and scale. The stock closed at $398.27, giving the company a market value near $84.6b.

Recent price action for Elevance Health points to building momentum, with a 1 month share price return of 6.74% and a year to date share price return of 12.43%. The 1 year total shareholder return of 30.33% contrasts with a weaker 3 year total shareholder return, which declined 9.71%.

If Elevance Health has you reviewing your healthcare exposure, it can also be useful to compare with other companies that are shaping the sector through AI driven care models using the 42 healthcare AI stocks.

Elevance Health runs a large health benefits and services platform, and the recent share price climb has put fresh attention on that scale. The real issue now is whether you are paying a fair price for that strength.

Most Popular Narrative: 11.3% Undervalued

At a last close of $398.27 against a narrative fair value of $449.10, Elevance Health is framed as undervalued, with that gap pinned on future margin and earnings potential rather than current returns.

Strategic investments in digital consumer engagement and Carelon's diversified health services (e.g., pharmacy, care management, behavioral health) are accelerating revenue growth and providing higher-margin, recurring income streams. These initiatives are expected to support both topline and earnings diversity as industry healthcare spending and complexity continue to rise.

Want to see what sits behind that earnings story for Elevance Health? The narrative focuses on steadier revenue, wider margins, and a lower future earnings multiple than many peers. Investors may be interested in how those moving parts are combined to arrive at that fair value estimate.

Result: Fair Value of $449.10 (UNDERVALUED)

However, Elevance Health still faces meaningful risks, including persistent Medicaid cost pressures and integration challenges in Carelon acquisitions that could limit the margin story investors are watching.

Next Steps

The mix of upside potential and real risks around Elevance Health has drawn strong views on both sides, so it makes sense to check the evidence yourself soon and decide where you stand. To see which rewards are driving optimism and pressure test your own thesis, start with the 4 key rewards.

Looking for more investment ideas beyond Elevance Health?

If Elevance Health has sharpened your focus on opportunities, do not stop here. Broaden your watchlist with other stocks that fit clear, disciplined criteria using the Simply Wall Street Screener.

• Target stronger value opportunities by reviewing companies highlighted in the 50 high quality undervalued stocks.
• Prioritise capital preservation first and see which stocks pass the 79 resilient stocks with low risk scores.
• Spot potential future leaders early by checking the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.